Julie Westerlin Kjeldsen
Julie Westerlin Kjeldsen
1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
1,#,
Cathrine Lund Lorentzen
Cathrine Lund Lorentzen
1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
1,#,
Evelina Martinenaite
Evelina Martinenaite
1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
2IO Biotech Aps, Copenhagen, Denmark
1,2,
Eva Ellebaek
Eva Ellebaek
1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
1,
Marco Donia
Marco Donia
1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
1,
Rikke Boedker Holmstroem
Rikke Boedker Holmstroem
1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
1,
Tobias Wirenfeldt Klausen
Tobias Wirenfeldt Klausen
1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
1,
Cecilie Oelvang Madsen
Cecilie Oelvang Madsen
1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
1,
Shamaila Munir Ahmed
Shamaila Munir Ahmed
1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
1,
Stine Emilie Weis-Banke
Stine Emilie Weis-Banke
1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
1,
Morten Orebo Holmström
Morten Orebo Holmström
1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
1,
Helle Westergren Hendel
Helle Westergren Hendel
3Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Herlev, Denmark
3,
Eva Ehrnrooth
Eva Ehrnrooth
2IO Biotech Aps, Copenhagen, Denmark
2,
Mai-Britt Zocca
Mai-Britt Zocca
2IO Biotech Aps, Copenhagen, Denmark
2,
Ayako Wakatsuki Pedersen
Ayako Wakatsuki Pedersen
2IO Biotech Aps, Copenhagen, Denmark
2,
Mads Hald Andersen
Mads Hald Andersen
1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
4Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
1,4,
Inge Marie Svane
Inge Marie Svane
1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
1,✉
1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
2IO Biotech Aps, Copenhagen, Denmark
3Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Herlev, Denmark
4Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
Subject terms: Phase II trials, Melanoma, Translational research, Peptide vaccines
© The Author(s) 2022
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
